Recital 13, Regulation (EU) 2022/20

In forcesince 7 Jan 2022

A risk-based approach should be taken as regards the frequency of screening of safety information, the extent of its assessment and the timelines of assessment and reporting. Risk adaptations should depend on the knowledge about the safety profile of the active substance. For example, active substances with a marketing authorisation in the Union may be screened less frequently in comparison to unauthorised active substances.